---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-002396"
form_type: "8-K"
ticker: "EXOZ"
cik: "0002010788"
company_name: "EXOZYMES INC."
filed_at: "2025-04-02T23:59:59+00:00"
generated_at: "2026-05-24T00:07:09.510900+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# eXoZymes provides Q4/FY2024 operational update; pre-revenue, advancing AI and commercialization

## Summary
- Completed IPO on Nasdaq on Nov 13, 2024; trades as EXOZ.
- Developed proprietary AI process to generate enzyme data, speeding up enzyme development.
- Focus on commercialization via spin-outs, joint ventures, and licensing deals.
- Remains pre-revenue; no financial results disclosed in the update.
- CEO cites milestones toward first commercial applications as key focus.

## SEC filing metadata
- accession: 0001641172-25-002396
- form_type: 8-K
- ticker: EXOZ
- cik: 0002010788
- company_name: EXOZYMES INC.
- filed_at: 2025-04-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2010788/000164117225002396/0001641172-25-002396-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2010788/000164117225002396/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-002396
- JSON: https://secwatch.observer/filing/0001641172-25-002396.json
- Plain text: https://secwatch.observer/filing/0001641172-25-002396.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.